Cardiovascular Risk in Chronic Kidney Disease (CKD), Risk factors for CKD progression, Endothelial dysfunction and hypertension in CKD and in End Stage Kidney Disease (ESKD), Epidemiology of kidney diseases
CNR (National Research Council of Italy)-Clinical Physiology Institute (Clinical Epidemiology of Renal Diseases and Hypertension Unit),
Carmine Zoccali (born January 1947) is an Italian nephrologist and a clinical investigator. He has contributed to research in several fields, most notably hypertension and cardiovascular complications in chronic kidney disease (CKD), CKD progression and clinical epidemiology of kidney diseases at large. He is known for his studies on cardiovascular risk in CKD and dialysis patients. He was among the earliest investigators that focused on the relevance of endothelial dysfunction[1] and inflammation[2] for the high risk of cardiovascular disease in these populations. In this research area, he was the first to link endogenous inhibitors of the nitric oxide system with death and cardiovascular disease.[3] and the first to document a relationship between sympathetic over-activity and these outcomes[4] Dr Zoccali is a practicing specialist in Nephrology, with a national qualification for the full professorship in Nephrology. He is also a specialist in hypertension, certified by the European Society of Hypertension (ESH).[5]
^Zoccali, Carmine; Benedetto, Francesco Antonio; Mallamaci, Francesca; Tripepi, Giovanni; Fermo, Isabella; Focà, Alfredo; Paroni, Rita; Malatino, Lorenzo Salvatore (September 2000). "Inflammation is associated with carotid atherosclerosis in dialysis patients". Journal of Hypertension. 18 (9): 1207–1213. doi:10.1097/00004872-200018090-00006. PMID10994751. S2CID30430138.
^Zoccali, Carmine; Bode-Böger, Stefanie M.; Mallamaci, Francesca; Benedetto, Frank Antonio; Tripepi, Giovanni; Malatino, Lorenzo Salvatore; Cataliotti, Alessandro; Bellanuova, Ignazio; Fermo, Isabella; Frölich, Jürgen C.; Böger, Rainer H. (22 December 2001). "Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study". The Lancet. 358 (9299): 2113–2117. doi:10.1016/S0140-6736(01)07217-8. PMID11784625. S2CID41178487.